The premarket trading price for Bionano Genomics Inc. (NASDAQ: BNGO) was up 5.75% at $6.25. A share of Bionano stock closed at $5.91 last session, increasing 9.85% or $0.53. BNGO stock traded between $5.16 and $5.96 on the day. There were 28.31 million shares exchanged, a number higher than the BNGO’s 50-day average daily volume of 27.34 million and roughly half of its average daily volume of 58.25 million since start of the year. BNGO stock has been surging since two UK government-affiliated laboratories joined its system.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
How did that happen?
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Genomic analysis company Bionano provides genomic expertise and services to clinicians conducting genetic research as well as diagnostic testing for ASD and other neuro-developmental disorders through its Lineagen business. A prototype of Bionano’s Saphyr system enables researchers and clinicians to discover new diagnostic biomarkers along with more efficiently study the changes in chromosomes, which scientists refer to as cytogenetics.
Read More
On Wednesday, Bionano Genomics announced that two large hospitals belonging to the United Kingdom National Health System (NHS) had decided to adopt its Saphyr system for optical genome mapping (OGM).
- NHS Regional Genetics Laboratory at Belfast City Hospital and King’s College Hospital in London are using Saphyr systems.
- BNGO’s Reagent Rental Program led these laboratories to adopt the system, which involves a commitment to purchase consumables for the system over time.
- Each site is using Saphyr to analyze the genomics of patients with heme malignancies.
- This Belfast site will test Saphyr for structural variant detection in patients with developmental delay, infertility, rare diseases, and other genetic diseases, too.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Going forward:
As time goes on, Bionano (BNGO) will be focusing more on speeding up the process for researchers to incorporate OGM into Saphyr to facilitate faster generation of data. With earlier access to Saphyr, BNGO will earn revenue quicker than it would with a traditional capital sales cycle.
